Preexisting immunity to the 2009 H1N1 influenza virus provided near-complete protection against severe H5N1 disease and ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's $1.6B acquisition ...

(Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the combination of tobevibart and elebsiran to continued ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

Kling Bio ("Kling" or "the Company"), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a collaboration and license option ...

PRESS RELEASE Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation Novel antibody, potravitug, demonstrates high neutralization of ...

Novel antibody, potravitug, demonstrates high neutralization of all BKPyV serotypes with potential to transform treatment for kidney transplant recipients with BKPyV infection Schlieren / Zurich ...

Novel antibody, potravitug, demonstrates high neutralization of all BKPyV serotypes with potential to transform treatment for kidney transplant recipients with BKPyV infection Schlieren / Zurich, ...